Wolfe upgrades Ionis to outperform, cites upcoming catalysts (NASDAQ:IONS)

Published on 10 Apr 2024 on Seeking Alpha

Wolfe Research upgraded Ionis (IONS) to outperform, citing revenue potential for its severe...

Read the rest of the article

Start tracking your investments with Statfolio

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, w...

Insider Monkey · via Yahoo Finance 21 Nov 2024

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we ...

Insider Monkey · via Yahoo Finance 19 Nov 2024

Despite a dip in quarterly revenue, Ionis Pharmaceuticals Inc (IONS) focuses on upcoming product...

GuruFocus.com · via Yahoo Finance 6 Nov 2024

We recently compiled a list of the 10 Stocks with Biggest Upside Potential According to Hedge Fun...

Insider Monkey · via Yahoo Finance 7 Oct 2024

Following this sale, the insider now owns 85,508 shares of Ionis Pharmaceuticals Inc. Over the pa...

GuruFocus.com · via Yahoo Finance 20 Aug 2024

Key Insights Ionis Pharmaceuticals' Annual General Meeting to take place on 6th of June Salary of...

Simply Wall St. · via Yahoo Finance 19 May 2024

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) shareholders are probably feeling a little disappointed...

Simply Wall St. via Yahoo Finance 9 May 2024

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2024 Earnings Call Transcript May 7, 2024 Ionis Phar...

Insider Monkey via Yahoo Finance 9 May 2024

Ionis Pharmaceuticals IONS reported a loss of 98 cents per share for first-quarter 2024, which wa...

Zacks via Yahoo Finance 8 May 2024

Insights from the First Quarter of 2024 13F Filing Tweedy Browne (Trades, Portfolio), a distingui...

GuruFocus.com via Yahoo Finance 7 May 2024